1887

Abstract

Serum RANTES (regulated on activation, normal T-cell expressed and secreted) concentrations were measured in 14 patients who had haematological malignancies and developed invasive fungal infections (three of them definite, eight probable and three possible). RANTES levels fell substantially from pre-chemotherapy values at the start of and throughout the fungal infection, and recovered in patients who survived the fungal infection. However, in patients who died from the invasive fungal infection, RANTES levels did not recover. For survivors the mean ± levels for RANTES were 7656 ± 877 pg ml on the day prior to chemotherapy, 3723 ± 2443 pg ml on the first day of fungal infection diagnosis (significantly different from baseline; = 0.001) and 9078 ± 2256 pg ml at recovery from the fungal infection (significantly different from lowest value; < 0.0001). Platelet counts were closely correlated with the RANTES levels ( = 0.63, < 0.001). The RANTES concentrations for the three patients who died were similar to those who survived at all equivalent timepoints, but were significantly lower at the time of death (792 ± 877) compared to the values at recovery for survivors ( = 0.005). The finding that patients who died from an invasive fungal infection had very low platelet counts and RANTES concentrations suggests that these could play a role in host response to such infections.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46121-0
2005-11-01
2019-12-16
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/11/JM541103.html?itemId=/content/journal/jmm/10.1099/jmm.0.46121-0&mimeType=html&fmt=ahah

References

  1. Anonymous ( 1992;). American College of Chest Physician/Society of Critical Care Medicine Consensus Conference definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Medicine 20, 864–874.[CrossRef]
    [Google Scholar]
  2. Ascioglu, S., Rex, G. H., de Pauw, B. & 17 other authors ( 2002;). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34, 7–14.[CrossRef]
    [Google Scholar]
  3. Balloy, V., Huerre, M., Latge, J. P. & Chignard, M. ( 2005;). Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 73, 494–503.[CrossRef]
    [Google Scholar]
  4. Blease, K., Mehrad, B., Standiford, T. J., Lukacs, N. W., Gosling, J., Boring, L., Charo, I. F., Kunkel, S. L. & Hogaboam, C.M. ( 2000;). Enhanced pulmonary allergic responses to Aspergillus in CCR2−/− mice. J Immunol 165, 2603–2611.[CrossRef]
    [Google Scholar]
  5. Cavaillon, J. M., Adib-Conquy, M., Fitting, C., Adrie, C. & Payen, D. ( 2003;). Cytokine cascade in sepsis. Scand J Infect Dis 35, 535–544.[CrossRef]
    [Google Scholar]
  6. Christin, L., Wysong, D. R., Meshulam, T., Hastey, R., Simons, E. R. & Diamond, R. D. ( 1998;). Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils. Infect Immun 66, 1181–1189.
    [Google Scholar]
  7. Coiffier, B., Lepage, E., Briere, J. & 10 other authors ( 2002;). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346, 235–242.[CrossRef]
    [Google Scholar]
  8. Denning, D. W. & Stevens, D. A. ( 1990;). Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12, 1147–1201.[CrossRef]
    [Google Scholar]
  9. Ellis, M. ( 2004;). Preventing microbial translocation in haematological malignancy. Br J Haematol 125, 282–293.[CrossRef]
    [Google Scholar]
  10. Farag, S. S., Rupert, A. S., Mrozek, K. & 15 other authors ( 2005;). Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group study. J Clin Oncol 23, 1–12.[CrossRef]
    [Google Scholar]
  11. Gerson, S. L., Talbot, G. H., Hurwitz, S., Strom, B. L., Lusk, E. J. & Cassileth, P. A. ( 1984;). Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100, 345–351.[CrossRef]
    [Google Scholar]
  12. Hughes, W. T., Armstrong, D., Bodey, G. P. & 8 other authors ( 2002;). 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34, 730–751.[CrossRef]
    [Google Scholar]
  13. Lin, S., Schranz, J. & Teutsch, S. M. ( 2001;). Aspergillosis case-fatality rate: systemic review of the literature. Clin Infect Dis 32, 358–366.[CrossRef]
    [Google Scholar]
  14. Mehrad, B., Moore, T. A. & Standiford, T. J. ( 2000;). Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. J Immunol 165, 962–968.[CrossRef]
    [Google Scholar]
  15. Puzniak, L., Teutsch, S., Powderley, W. & Polish, L. ( 2004;). Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 25, 628–633.[CrossRef]
    [Google Scholar]
  16. Rex, J. H., Bennett, J. E., Gallin, J. I., Malech, H. L. & Melnick, D. A. ( 1990;). Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 162, 523–528.[CrossRef]
    [Google Scholar]
  17. Rowe, J. M. ( 1998;). Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin Infect Dis 26, 1290–1294.[CrossRef]
    [Google Scholar]
  18. Schaffner, A., Douglas, H. & Braude, A. ( 1982;). Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus.Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 69, 617–631.[CrossRef]
    [Google Scholar]
  19. Schall, T. J. ( 1991;). Biology of the RANTES/SIS cytokine family. Cytokine 3, 165–183.[CrossRef]
    [Google Scholar]
  20. Sozzani, S., Luini, W., Borsatti, A. & 9 other authors ( 1997;). Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159, 1993–2000.
    [Google Scholar]
  21. Traynor, T. R., Herring, A. C., Dorf, M. E., Kuziel, W. A., Toews, G. B. & Huffnagle, G. B. ( 2002;). Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J Immunol 168, 4659–4666.[CrossRef]
    [Google Scholar]
  22. van Spriel, A. B., van den Herik-Oudijk, I. E. & van de Winkel, J. G. ( 2001;). Neutrophil Fc gamma RI as target for immunotherapy of invasive candidiasis. J Immunol 166, 7019–7022.[CrossRef]
    [Google Scholar]
  23. von Hundelshausen, P., Weber, K. S., Huo, Y., Proudfoot, A. E., Nelson, P. J., Ley, K. & Weber, C. ( 2001;). RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103, 1772–1777.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46121-0
Loading
/content/journal/jmm/10.1099/jmm.0.46121-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error